 |
|
Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events
VA-HIT: A Randomized Controlled Trial
Sander J. Robins, MD;
Dorothea Collins, ScD;
Janet T. Wittes, PhD;
Vasilios Papademetriou, MD;
Prakash C. Deedwania, MD;
Ernst J. Schaefer, MD;
Judith R. McNamara, MT;
Moti L. Kashyap, MD;
Jerome M. Hershman, MD;
Laura F. Wexler, MD;
Hanna Bloomfield Rubins, MD,MPH;
for the VA-HIT Study Group
JAMA. 2001;285:1585-1591.
ABSTRACT
| |
Context A low plasma level of high-density lipoprotein cholesterol (HDL-C) is a major risk factor for coronary heart disease (CHD). A secondary prevention study, the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT), demonstrated that CHD events were significantly reduced during a median follow-up of 5.1 years by treating patients with the fibric acid derivative gemfibrozil when the predominant lipid abnormality was low HDL-C.
Objective To determine if the reduction in major CHD events with gemfibrozil in VA-HIT could be attributed to changes in major plasma lipid levels.
Design Multicenter, randomized, double-blind, placebo-controlled trial conducted from September 1991 to August 1998.
Setting The Department of Veterans Affairs Cooperative Studies Program, in which 20 VA medical centers were participating sites.
Participants A total of 2531 men with a history of CHD who had low HDL-C levels (mean, 32 mg/dL [0.83 mmol/L] ) and low low-density lipoprotein cholesterol (LDL-C) levels (mean, 111 mg/dL [2.88 mmol/L]).
Intervention Participants were randomly assigned to receive gemfibrozil, 1200 mg/d (n = 1264), or matching placebo (n = 1267).
Main Outcome Measure Relation of lipid levels at baseline and averaged during the first 18 months of gemfibrozil treatment with the combined incidence of nonfatal myocardial infarction and CHD death.
Results Concentrations of HDL-C were inversely related to CHD events. Multivariable Cox proportional hazards analysis showed that CHD events were reduced by 11% with gemfibrozil for every 5-mg/dL (0.13-mmol/L) increase in HDL-C (P = .02). Events were reduced even further with gemfibrozil beyond that explained by increases in HDL-C values, particularly in the second through fourth quintiles of HDL-C values during treatment. During gemfibrozil treatment, only the increase in HDL-C significantly predicted a lower risk of CHD events; by multivariable analysis, neither triglyceride nor LDL-C levels at baseline or during the trial predicted CHD events.
Conclusions Concentrations of HDL-C achieved with gemfibrozil treatment predicted a significant reduction in CHD events in patients with low HDL-C levels. However, the change in HDL-C levels only partially explained the beneficial effect of gemfibrozil.
INTRODUCTION
Considerable epidemiologic data show that a low concentration of plasma high-density lipoprotein cholesterol (HDL-C) is a major risk factor for coronary heart disease (CHD).1-4 In the United States, a low HDL-C concentration is the most prevalent lipid abnormality in men with known CHD.5-6 Moreover, a low HDL-C level better distinguishes populations with and without CHD than does a high level of low-density lipoprotein cholesterol (LDL-C).7-8 The VA High-Density Lipoprotein Intervention Trial (VA-HIT) was undertaken to test the hypothesis that drug therapy to increase a low HDL-C level would decrease the incidence of major CHD events.9
A total of 2531 men with known CHD and low levels of HDL-C and LDL-C were recruited for VA-HIT and treated with either the fibric acid derivative gemfibrozil or placebo (Figure 1). Treatment with gemfibrozil at a dosage of 1200 mg/d resulted in a 22% reduction in the primary end point, the combined incidence of nonfatal myocardial infarction (MI) and CHD death, during a median follow-up of 5.1 years.9 The relative reduction in these CHD events with gemfibrozil was virtually the same as reported for recent secondary prevention trials with statin therapy in patients with modestly high LDL-C concentrations.10-11
|
|
|
|
Figure 1. Participant Flow Through the Study
CHD indicates coronary heart disease.
|
|
|
At baseline in VA-HIT, gemfibrozil and placebo groups were evenly matched for clinical characteristics and laboratory values and had the following mean fasting lipid values: total cholesterol, 175 mg/dL (4.53 mmol/L); triglycerides, 162 mg/dL (1.82 mmol/L); LDL-C, 111 mg/dL (2.88 mmol/L); and HDL-C, 32 mg/dL (0.83 mmol/L). As previously reported,9 in this population treatment with gemfibrozil, compared with placebo, produced after 1 year an average increase in HDL-C of 6%, a decrease in triglycerides of 31%, and no change in LDL-C.
Other clinical end point trials have been conducted with drugs that have a prominent effect on HDL-C and triglycerides, most particularly fibric acids12-18 or niacin.15-16 However, subjects in these trials have also had relatively high concentrations of total cholesterol or LDL-C and, when measured, concentrations of HDL-C that have not been in a distinctly low range. In sharp contrast to subjects in previous trials, participants in VA-HIT were recruited who had low LDL-C ( 140 mg/dL [3.63 mmol/L]) as well as low HDL-C (40 mg/dL [1.04 mmol/L]) levels. Participants also had a broad range of triglyceride values (300 mg/dL [3.38 mmol/L]), representative of triglycerides in 75% to 80% of men with CHD in the United States.6
Gemfibrozil, like other fibric acid derivatives, has a wide range of potentially favorable effects on lipoprotein metabolism.19 The most consistent plasma lipid changes that result from gemfibrozil treatment are an increase in HDL-C and a decrease in triglycerides, changes that are in great part reciprocally related and secondary to the activation by gemfibrozil of the lipolysis of triglyceride-rich lipoproteins. Gemfibrozil may also increase plasma HDL-C by decreasing cholesteryl ester transfer protein–mediated cholesterol exchange from HDL20-21 and by directly stimulating hepatic HDL synthesis and secretion.22 In addition to changes in HDL that are closely linked to triglycerides, like other fibric acids gemfibrozil will activate peroxisome proliferator–activated nuclear receptors that may result in other favorable effects on vascular function, which may be largely independent of changes in HDL concentration.23
The present analysis was performed to determine if the reduction in major CHD events in VA-HIT could be correlated with the concentrations of lipids at baseline, during the trial, and the changes in these lipids with gemfibrozil treatment.
METHODS
The general design and procedures of VA-HIT have been previously reported.24 The trial was conducted from September 1991 through August 1998 in 20 VA medical centers. The primary combined end point, nonfatal MI and CHD death, was adjudicated by an independent committee blinded to treatment assignment. A central laboratory performed all lipid analyses once subjects had been randomized. Laboratory personnel were blinded to treatment and participant identification. This study was approved by the human rights committee of the Cooperative Studies Program Coordinating Center and by each study site's institutional review board. Each participant gave written informed consent.
Lipid Measurement
Before medication was dispensed, lipid levels were determined twice and averaged to obtain a baseline value. Major lipid concentrations (consisting of HDL-C, triglycerides, and LDL-C) were determined during the trial at 4, 7, 12, 18, 24, 36, 48, and 60 months. Values obtained at the 4- through 18-month visits were averaged and used for trial results in accord with our original protocol design that postulated a 2-year lag in treatment benefit and with the rationale that these earliest samples were obtained before an appreciable number of new CHD events had occurred. If an end point occurred before 18 months, only values up to the time of an end point were averaged to avoid a lipid change that might have been influenced by a new CHD event.
Lipids were measured after subjects had fasted for 12 to 14 hours. Blood samples were prepared using EDTA as an anticoagulant and plasma was mailed frozen from individual study sites to the central laboratory. Total cholesterol, HDL-C, and triglycerides were determined by standardized automated enzymatic methods25 and LDL-C was calculated by the Friedewald formula.26 Levels of LDL-C were not calculated if triglycerides were higher than 400 mg/dL (4.51 mmol/L). HDL-C was isolated by precipitation with dextran-Mg2+.27 Apolipoprotein (apo) A-I, apoB, HDL2-C, and HDL3-C concentrations were determined at baseline and during the trial at the 12-month follow-up visit.
The mean coefficient of variation for the measurements of cholesterol, triglycerides, and HDL-C was <2%, <3%, and <4%, respectively. Levels of apoA-I and apoB were determined by immunoturbidometric precipitation methods28-29 and HDL subfractions were separated by differential polyanion precipitation.30 All results were sent to the VA Cooperative Studies Coordinating Center (West Haven, Conn) and entered into a VA-HIT centralized database.
Statistical Analysis
All analyses that relate plasma lipids and apolipoproteins at baseline and during the trial to the development of a new CHD event were performed according to the principle of intention-to-treat and using the combined incidence of nonfatal MI and CHD death, the primary VA-HIT outcome measure. The incidence of CHD events was obtained using the Kaplan-Meier survival method for tertile divisions of baseline and quintile divisions of trial concentrations of HDL-C, triglycerides, and LDL-C. Relative risks (RRs) for concentrations and changes in lipids were calculated from Cox proportional hazards models31 adjusting for treatment category and the major CHD risk factors of age, diabetes, hypertension, smoking, and body mass index. Compliance with therapy, as assessed by pill counts,24 did not significantly predict a primary CHD event and was not used in risk calculation. Models with baseline and trial lipid levels were separately constructed to assess the significance of individual lipids and apolipoproteins as univariable predictors of risk and, for the major plasma lipids (HDL-C, triglycerides, and LDL-C), as a multivariable set of variables to predict risk. Interaction between treatment and plasma lipids or apolipoproteins at baseline or during the trial were tested 1 at a time using separate Cox models. Relative risks with 95% confidence intervals (CIs) and corresponding P values are shown for all Cox results. Quintile comparisons were performed using log-rank tests to compare survival curves.
RESULTS
Lipid data were available for 2521 men at baseline (99.6% of the cohort) and for 2375 subjects from at least 1 of the 4 follow-up visits. The distribution at baseline of plasma HDL-C, triglyceride, and LDL-C values was similar in the placebo and gemfibrozil treatment groups.32 In this population, selected to have a restricted range of lipid values, mean (SD) values were nearly identical to median values for HDL-C (mean, 32 [5] mg/dL [0.83 {0.13} mmol/L] and median, 31 mg/dL [0.80 mmol/L]) and LDL-C (mean, 111 [22] mg/dL [2.88 {0.57} mmol/L] and median, 112 mg/dL [2.90 mmol/L]), and closely corresponded to median values for triglycerides (mean, 161 [68] mg/dL [1.81 {0.77} mmol/L] and median, 151 mg/dL [1.70 mmol/L]). As previously shown,9 with treatment the mean values of HDL-C, triglycerides, and LDL-C in both placebo and gemfibrozil groups remained nearly constant from 12 months to the end of the study at 60 months.
Lipid Changes With Gemfibrozil
Baseline and trial lipid and apolipoprotein values are shown in Table 1. Most notable was the significant increase in HDL-C, the decrease in triglycerides, and the absence of a change in LDL-C concentrations with gemfibrozil therapy. During the study, plasma apoB concentrations were lower with gemfibrozil therapy than with placebo. In contrast, apoA-I concentrations were the same in both groups. With gemfibrozil, HDL3-C, the major subfraction of HDL-C isolated by polyanion precipitation, was increased compared with placebo while HDL2-C, the minor subfraction, was decreased.
|
|
|
|
Table 1. Levels of Lipids and Apolipoproteins at Baseline and During the Trial*
|
|
|
Relation of CHD Events to Baseline Lipid Values
The relation of CHD events in placebo and gemfibrozil groups to baseline concentrations of HDL-C, triglycerides, and LDL-C is shown in Figure 2. Lipids were stratified as tertiles. In the placebo group, CHD events were higher than the overall mean event rate for this group in the lowest tertile of HDL-C and the highest tertiles of triglycerides and LDL-C. With gemfibrozil, there was a reduction in the RR of a CHD event for each tertile of each lipid, except for the lowest tertile of LDL-C.
|
|
|
|
Figure 2. Relation of the 5-Year Incidence of CHD Events to Baseline Lipid Values
Incidence rates were obtained from Kaplan-Meier survival curves for each tertile division of each lipid for placebo or gemfibrozil. For each treatment and at each tertile an interquartile range is shown for the median event rate. The overall event rate for subjects taking placebo is shown by the upper dashed lines and for gemfibrozil by the lower dashed lines. The relative risk reduction (RRR) of coronary heart disease (CHD) events with 95% confidence intervals (CIs) with gemfibrozil was calculated using Cox proportional hazards analysis for each tertile and is shown under the range of values for each tertile. HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. To convert mg/dL to mmol/L, multiply HDL-C and LDL-C values by 0.02586 and triglyceride values by 0.01127.
|
|
|
Relation of CHD Events to Lipid Values During the Trial
Subjects in the placebo and gemfibrozil groups were subdivided into quintiles by trial values of HDL-C, triglycerides, and LDL-C to relate the concentrations of these lipids to the 5-year incidence of nonfatal MI or CHD death (Figure 3). With placebo, the incidence of CHD events was inversely related to trial HDL-C levels (log-rank test, P = .01 comparing quintile 1 with 5) but was unrelated to levels of triglycerides (log-rank test, P = .93) and LDL-C (log-rank test, P = .49 for comparison of quintiles 1 and 5).
|
|
|
|
Figure 3. Relation of the 5-Year Incidence of CHD Events to HDL-C, Triglyceride, and LDL-C Values Achieved With Placebo or Gemfibrozil
Incidence rates were obtained from Kaplan-Meier survival curves for each quintile of values. The median event rates with interquartile ranges are plotted for the quintiles of the average of lipid values at 4- through 18-month follow-up. To obtain near-even numbers of subjects in each quintile, the placebo and gemfibrozil groups were separately subdivided. The relation of the incidence of coronary heart disease (CHD) events to trial values of high-density lipoprotein cholesterol (HDL-C), triglycerides, and low-density lipoprotein cholesterol (LDL-C) is shown by best-fit curves. To convert mg/dL to mmol/L, multiply HDL-C and LDL-C values by 0.02586 and triglycerides by 0.01127.
|
|
|
With gemfibrozil, there was a marked reduction in CHD events compared with placebo for the second through fourth quintiles of HDL-C levels (P = .02), whereas event rates in the 2 treatment groups did not differ at the lowest and highest HDL-C quintiles. With respect to triglycerides, event rates in the gemfibrozil group did not differ across the lowest 4 quintiles and were decidedly lower than for subjects taking placebo. Only with triglycerides in the highest quintile range with gemfibrozil was the CHD event rate the same as with placebo. Finally, with gemfibrozil, the incidence of CHD events did not differ across the quintile range of LDL-C levels. For all levels of LDL-C, subjects in the gemfibrozil group had a lower CHD event rate than those taking placebo.
RR of CHD Events From Cox Proportional Hazards Models
The RR of a new primary CHD event was determined for individual lipid and apolipoprotein variables at baseline and during the trial by Cox models, adjusted for treatment group and for major CHD risk factors (Table 2). At baseline, the concentrations of HDL-C, triglycerides, the HDL3-C subfraction, apoA-I, and apoB were all significant predictors of a new CHD event, whereas during the trial, only concentrations of HDL-C significantly predicted a CHD end point. Neither the change by concentration nor by percentage in HDL-C, the HDL2-C subfraction, triglycerides, LDL-C, or apolipoproteins were significant predictors of CHD risk. Although the trial concentration of HDL3-C did not predict CHD risk (P = .07), the percentage change in the HDL3-C subfraction was significantly related to the probability of a CHD event (P = .01).
|
|
|
|
Table 2. Plasma Lipids and Apolipoproteins as Predictors of Nonfatal MI and CHD Mortality*
|
|
|
Table 3 shows the results of multivariable analyses performed with the 3 major lipid variables at baseline and during the trial. These models were constructed to exclude apolipoproteins and HDL subfractions because these closely related components of the 3 major lipid variables could be expected to change the predictive relationship of a major lipid. Adjustment was made for treatment category, which showed no significant interaction with any of the major lipids, and for CHD risk factors. There was no significant interaction between HDL-C and triglycerides either at baseline or during the trial. Although HDL-C, triglyceride, and LDL-C concentrations at baseline were not significantly related to the development of a CHD event, the concentration of HDL-C achieved with therapy was strongly related to a reduction in CHD events. The RR reduction in CHD end points for a 5-mg/dL (0.13-mmol/L) increase in HDL-C with gemfibrozil was 11%.
|
|
|
|
Table 3. Major Plasma Lipids as Multivariable Predictors of Nonfatal MI and CHD Mortality*
|
|
|
We estimated that, together, the concentrations of HDL-C, triglycerides, and LDL-C achieved with therapy made a relatively small contribution to the overall decrease of a primary CHD event with gemfibrozil. That is, the RR of a CHD event with treatment as the only variable in regression analysis was 0.78 (95% CI, 0.66-0.94). The RR of a CHD event attributed to treatment itself should be lessened by the inclusion of other variables in this kind of analysis that would provide explanation for the benefit of treatment. In a regression model that included trial lipid values with treatment category, the RR of a CHD event was 0.83 (95% CI, 0.68-1.02), which would indicate that 77% ([1 - 0.83]/[1 - 0.78]) of the benefit of gemfibrozil was unexplained or that, at most, the lipid concentrations achieved with gemfibrozil could account for only 23% of the treatment benefit.
COMMENT
VA-HIT was undertaken to determine if raising HDL-C concentrations would decrease major coronary events in a high-risk group of men with low HDL-C. Treatment with gemfibrozil resulted in a significant reduction in CHD events during a 5-year period of follow-up in conjunction with an increase in HDL-C, a decrease in triglycerides, and no change in LDL-C levels.9 We now show that in VA-HIT the reduction in nonfatal MI and CHD death was strongly correlated with treatment concentrations of HDL-C but not triglycerides or LDL-C. In multivariable analysis, adjusting for the CHD risk factors of diabetes, hypertension, smoking, age, and body mass index, the only major lipid to predict a significant reduction in CHD events was HDL-C.
A notable finding of VA-HIT was that with multivariable analysis, neither baseline nor treatment triglyceride levels predicted CHD events (Table 3). A similar conclusion was reported in the Helsinki Heart Study,33 which found equally profound reductions in triglycerides with gemfibrozil as in VA-HIT (on the order of 30%) but no independent benefit of triglyceride reduction. Furthermore, even as a single lipid variable, VA-HIT triglyceride concentrations during treatment were not significantly related to the occurrence of a coronary event (Table 2).
Contrary to these trial results, we did find that baseline triglycerides as a single lipid variable had a significant relationship to the development of CHD events (Table 2) and that the event rate was highest at the highest tertile level of triglycerides at baseline (Figure 2). Moreover, at this highest tertile level of baseline triglycerides, gemfibrozil resulted in a significant reduction in CHD events (RR reduction of 28%). This observation is consistent with the Bezafibrate Infarction Prevention Study18 that, like VA-HIT, found a higher event rate and also a significant benefit of fibrate therapy in the subgroup of patients with the highest baseline values of triglycerides.
In VA-HIT we found that the subfraction HDL3-C, but not HDL2-C, at baseline and as a percentage change with therapy was significantly related to the development of new CHD events. Fibrates selectively increase HDL3,34-35 the subfraction of HDL that is smaller and relatively poorer in free cholesterol than HDL2 and, consequently, more likely to initiate free cholesterol efflux from peripheral tissue sites than HDL2 in the process of reverse cholesterol transport.36-37 Although HDL3-C and total HDL-C are strongly correlated, 4 angiographic intervention trials have shown HDL3-C to be a better predictor of coronary lesion progression than total HDL-C.38-41 Those results coincide with our finding in VA-HIT that baseline concentrations of HDL3-C were more strongly related to a CHD event than total HDL-C (Table 2).
We designed VA-HIT to exclude patients with a high concentration of LDL-C. With gemfibrozil, concentrations of LDL-C were not changed compared with placebo nor were CHD events significantly related to baseline or trial LDL-C concentrations. Moreover, concentrations of apoB, the component of LDL that has been found to be strongly correlated with a reduction in CHD risk when LDL-C is decreased with therapy,42 had no significant relation to the development of a CHD event.
The absence of any discernible effect on LDL-C concentrations distinguishes VA-HIT from previous lipid intervention trials that have demonstrated a reduction in CHD end points or improvement in angiographic end points with drug therapy. In other trials in which changes in HDL-C (or a major subfraction of HDL) could be statistically shown to contribute to a reduction in CHD or angiographic events, subjects have had higher than desirable LDL-C (or higher total cholesterol) at entry and/or reductions in LDL-C (or total cholesterol) with drug therapy that clearly played a part in CHD event reduction. These include the Helsinki Heart Study,17 the only other large clinical end point trial that has shown a significant benefit of increasing HDL-C, AFCAPS/TexCAPS,43 which showed a significant benefit of increasing apoA-I, and a number of trials in which drug therapy improved angiographic end points.38, 40-41,44-46
Our analyses have several potential limitations. First, our trial was confined to men with CHD and a lipid profile that excluded those with either a high LDL-C (>140 mg/dL [3.6 mmol/L]) or a high level of triglycerides (>300 mg/dL [3.4 mmol/L]). We have previously justified our exclusion of women on the basis of finding relatively few women with CHD and low HDL-C levels in the VA health care system when this trial was begun.24 We also have justified our exclusion of persons with a high LDL-C level to avoid the possibility that these individuals might be treated with another active drug to lower those levels. Our exclusion of persons with high triglyceride levels was based on the relative infrequency of triglycerides higher than 300 mg/dL in a survey that we conducted of 8500 men with known CHD,6 in which only 12.8% had triglycerides higher than 300 mg/dL and only 4.1% had triglycerides higher than 300 mg/dL together with a low level of LDL-C.
We believe that our analyses have many strengths that prominently include our exclusive use of the primary adjudicated end point of this trial, the combined incidence of nonfatal MI and CHD death, to define a new CHD event and our adherence to analyses by intention-to-treat, which preserved our strict randomization scheme.
An important practical issue relates to the extent to which the results of VA-HIT can be extrapolated to other kinds of therapy that also have the property of increasing HDL-C levels. For example, would statins, niacin, or certain lifestyle changes such as weight loss, which also increase HDL-C, be anticipated to have the same beneficial effect as gemfibrozil in the clinical context of VA-HIT? The data we have presented would strongly argue that it is not possible to assume that based on only an HDL-C response, a clinical outcome comparable to VA-HIT could be achieved with another kind of therapy. First, we have shown that at the same trial levels of HDL-C and in a relatively low range of HDL-C, there were fewer CHD events with gemfibrozil than with placebo. Second, we have shown that trial lipid levels as variables in a multivariable model can explain only 23% of the favorable effect of gemfibrozil. Although the results of VA-HIT clearly show that clinical benefit is correlated with higher values of HDL-C, fibrates produce a variety of other potentially favorable metabolic changes mediated in part through the activation of peroxisome proliferator–activated receptors.23
In summary, VA-HIT, which was conducted with the fibric acid derivative gemfibrozil, is the first lipid intervention trial to show that raising HDL-C concentrations in persons with established CHD and both a low HDL-C and a low LDL-C level will significantly reduce the incidence of major coronary events. We have demonstrated that a reduction in new coronary events is at least partly dependent on the concentration of HDL-C achieved with gemfibrozil and that the benefit of this therapy is independent of changes in the concentration of triglycerides or LDL-C.
AUTHOR INFORMATION
Financial Disclosures: Dr Robins serves as a consultant to Fournier Pharma; Dr Schaefer serves on the speaker's bureau and as a consultant to Pfizer, is a consultant to AstraZeneca, B. Braun of America, and Schering-Plough, serves on the speaker's bureau for Kos Pharmaceuticals Inc, and has received grants from Parke-Davis, Kos, and Pfizer; Dr Wittes serves as a consultant to the Department of Veterans Affairs; Ms McNamara serves or has served as a consultant to Sigma Diagnostics, Otsuka America Pharmaceutical, Glaxo Wellcome, and Schering-Plough; and Dr Kashyap has received grants from Parke-Davis and is on the speaker's bureau for Kos. Drs Robins, Collins, and Rubins have a US patent pending pertaining to the new use of a fibrate in the treatment of low HDL-C levels for the prevention of atherothrombotic events.
Author Contributions: Dr Robins, as coprincipal investigator of this study, had full access to all the data in this study and takes full responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Robins, Collins, Wittes, Schaefer, Rubins.
Acquisition of data: Robins, Collins, Papademetriou, Deedwania, Schaefer, McNamara, Kashyap, Wexler.
Analysis and interpretation of data: Robins, Collins, Wittes, Papademetriou, Deedwania, McNamara, Kashyap, Hershman, Rubins.
Drafting of the manuscript: Robins, Collins, Rubins.
Critical revision of the manuscript for important intellectual content: Robins, Collins, Wittes, Deedwania, Schaefer, McNamara, Kashyap, Hershman, Wexler, Rubins.
Statistical expertise: Collins, Wittes.
Obtained funding: Robins, Rubins.
Administrative, technical, or material support: Robins, Collins, Papademetriou, Deedwania, Schaefer, McNamara, Wexler, Rubins.
Study supervision: Robins, Collins, Rubins.
Funding/Support: The VA-HIT was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development and by a supplemental grant from Parke-Davis Pharmaceuticals. Parke-Davis supplied the gemfibrozil and matching placebo for this study.
Corresponding Author and Reprints: Sander J. Robins, MD, Section of Endocrinology, Nutrition, and Diabetes, Evans 204, Boston University School of Medicine, 88 E Newton St, Boston, MA 02118 (e-mail: sjrobins{at}bu.edu).
Author Affiliations: Department of Medicine, Boston University School of Medicine, Boston, Mass (Dr Robins); VAMC Cooperative Studies Program Coordinating Center, West Haven, Conn (Dr Collins); Statistics Collaborative, Washington, DC (Dr Wittes); Lipid Research Laboratory, Tufts University School of Medicine, Boston (Dr Schaefer and Ms McNamara); and Departments of Medicine, Veterans Affairs Medical Centers, Washington, DC (Dr Papademetriou), Fresno, Calif (Dr Deedwania), Long Beach, Calif (Dr Kashyap), Los Angeles, Calif (Dr Hershman), Cincinnati, Ohio (Dr Wexler), and Minneapolis, Minn (Dr Rubins).
A listing of the members of the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) was published previously (N Engl J Med. 1999;341:417-418).
REFERENCES
| |
1. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1:16-25.
FULL TEXT
|
ISI
| PUBMED
2. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Circulation. 1989;79:8-15.
FREE FULL TEXT
3. Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apoproteins and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
ABSTRACT
4. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. Arterioscler Thromb Vasc Biol. 1997;17:107-113.
FREE FULL TEXT
5. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995;76:69C-77C.
6. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol. 1995;75:1196-1201.
FULL TEXT
|
ISI
| PUBMED
7. Genest J Jr, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992;19:792-802.
ABSTRACT
8. Lamarche B, Despres J-P, Moorjani S, et al. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Atherosclerosis. 1996;119:235-245.
FULL TEXT
|
ISI
| PUBMED
9. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
FREE FULL TEXT
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
FREE FULL TEXT
11. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
FREE FULL TEXT
12. Group of Physicians of the Newcastle upon Tyne Region. Trial of clofibrate in the treatment of ischaemic heart disease. BMJ. 1971;4:767-775.
FREE FULL TEXT
13. Research Committee of the Scottish Society of Physicians. Ischaemic heart disease. BMJ. 1971;4:775-784.
FREE FULL TEXT
14. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J. 1978;40:1069-1118.
FREE FULL TEXT
15. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
FREE FULL TEXT
16. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
ISI
| PUBMED
17. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
ABSTRACT
18. The BIP Study Group. Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation. 2000;102:21-27.
FREE FULL TEXT
19. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
FREE FULL TEXT
20. Ponsin G, Girardot G, Berthezene F. Mechanism of the gemfibrozil-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins. Biochem Med Metab Biol. 1994;52:58-64.
FULL TEXT
|
ISI
| PUBMED
21. Franceschini G, Lovati MR, Manzoni C, et al. Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. Atherosclerosis. 1995;114:61-71.
FULL TEXT
|
ISI
| PUBMED
22. Saku K, Gartside PS, Hynd BA, Kashyap ML. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest. 1985;75:1702-1712.
ISI
| PUBMED
23. Fruchart J-C, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 1999;10:245-257.
FULL TEXT
|
ISI
| PUBMED
24. Rubins HB, Robins SJ, Iwane MK, et al. Rationale and design of the Department of Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol. 1993;71:45-52.
FULL TEXT
|
ISI
| PUBMED
25. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta. 1987;166:1-8.
FULL TEXT
|
ISI
| PUBMED
26. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
ABSTRACT
27. McNamara JR, Huang C, Massov T, et al. Modification of the dextran-Mg2+ HDL cholesterol precipitation method for use with previously frozen plasma. Clin Chem. 1994;40:233-239.
FREE FULL TEXT
28. Contois JH, McNamara JR, Lammi-Keefe CJ, et al. Reference intervals for plasma apolipoprotein A-I as determined with a commercially available immunoturbidometric assay. Clin Chem. 1996;42:507-514.
FREE FULL TEXT
29. Contois JH, McNamara JR, Lammi-Keefe CJ, et al. Reference intervals for plasma apolipoprotein B as determined with a commercially available immunoturbidometric assay. Clin Chem. 1996;42:515-523.
FREE FULL TEXT
30. Nguyen T, Warnick GR. Improved methods for separation of total HDL and subclasses [abstract]. Clin Chem. 1989;35:1086.
31. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187-202.
32. Rubins HB, Robins SJ, Collins D for the Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group. Baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol. 1996;78:572-575.
FULL TEXT
|
ISI
| PUBMED
33. Manninen V, Elo O, Frick H, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
FREE FULL TEXT
34. Sorisky A, Ooi TC, Simo IE, et al. Change in composition of high density lipoprotein during gemfibrozil therapy. Atherosclerosis. 1987;67:181-189.
FULL TEXT
|
ISI
| PUBMED
35. Manttari M, Koskinen P, Manninen V, et al. Effect of gemfibrozil on the concentration and composition of serum lipoproteins. Atherosclerosis. 1990;81:11-17.
FULL TEXT
|
ISI
| PUBMED
36. Fielding CJ. Early events in the transfer of cell-derived cholesterol to human plasma. In: Miller NE, ed. High Density Lipoprotein and Atherosclerosis II. Amsterdam, the Netherlands: Elsevier; 1989:149-158.
37. Castro Cabezas M, van Heusden GPH, de Bruin TWA, et al. Reverse cholesterol transport: relationship between free cholesterol uptake and HDL3 in normolipidaemic and hyperlipidaemic subjects. Eur J Clin Invest. 1993;23:122-129.
ISI
| PUBMED
38. Watts GF, Mandalia S, Brunt JNH, et al. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St Thomas' Atherosclerosis Regression Study (STARS). Metabolism. 1993;42:1461-1467.
FULL TEXT
|
ISI
| PUBMED
39. Syvanne M, Nieminen MS, Frick MH, et al. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation. 1998;98:1993-1999.
FREE FULL TEXT
40. Ballantyne CM, Herd A, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation. 1999;99:736-743.
FREE FULL TEXT
41. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS): treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol. 1996;16:697-704.
FREE FULL TEXT
42. Sehayek E, Eisenberg S. The role of native apolipoprotein B-containing lipoproteins in atherosclerosis. Curr Opin Lipidol. 1994;5:350-353.
PUBMED
43. Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in AFCAPS/TexCAPS. Circulation. 2000;101:477-484.
FREE FULL TEXT
44. Blankenhorn DH, Alaupovic P, Wickham E, et al. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Circulation. 1990;81:470-476.
FREE FULL TEXT
45. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
ABSTRACT
46. Ruotolo G, Ericson CG, Tettamanti C, et al. Treatment effects on serum lipoproteins, lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol. 1998;32:1648-1656.
FREE FULL TEXT
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
March 28, 2001
JAMA. 2001;285(12):1649-1650.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Evaluating the Incremental Benefits of Raising High-Density Lipoprotein Cholesterol Levels During Lipid Therapy After Adjustment for the Reductions in Other Blood Lipid Levels
Grover et al.
Arch Intern Med 2009;169:1775-1780.
ABSTRACT
| FULL TEXT
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
Chapman et al.
Eur Heart J 2009;0:ehp399v1-ehp399.
ABSTRACT
| FULL TEXT
Pleiotropic Action of Short-Term Metformin and Fenofibrate Treatment, Combined With Lifestyle Intervention, in Type 2 Diabetic Patients With Mixed Dyslipidemia
Pruski et al.
Diabetes Care 2009;32:1421-1424.
ABSTRACT
| FULL TEXT
Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1
Zhu et al.
J. Lipid Res. 2009;50:1330-1339.
ABSTRACT
| FULL TEXT
Long-term Benefit of High-Density Lipoprotein Cholesterol-Raising Therapy With Bezafibrate: 16-Year Mortality Follow-up of the Bezafibrate Infarction Prevention Trial
Goldenberg et al.
Arch Intern Med 2009;169:508-514.
ABSTRACT
| FULL TEXT
Effect of Rimonabant on the High-Triglyceride/ Low-HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat: The ADAGIO-Lipids Trial
Despres et al.
Arterioscler. Thromb. Vasc. Bio. 2009;29:416-423.
ABSTRACT
| FULL TEXT
Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis
Briel et al.
BMJ 2009;338:b92-b92.
ABSTRACT
| FULL TEXT
Effect of a Low-Glycemic Index or a High-Cereal Fiber Diet on Type 2 Diabetes: A Randomized Trial
Jenkins et al.
JAMA 2008;300:2742-2753.
ABSTRACT
| FULL TEXT
Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
Nicholls et al.
Circulation 2008;118:2506-2514.
ABSTRACT
| FULL TEXT
Nonfasting Triglycerides and Risk of Ischemic Stroke in the General Population
Freiberg et al.
JAMA 2008;300:2142-2152.
ABSTRACT
| FULL TEXT
Investigation and management of hypertriglyceridaemia
Ferns et al.
J. Clin. Pathol. 2008;61:1174-1183.
ABSTRACT
| FULL TEXT
Lipoprotein Particle Concentrations May Explain the Absence of Coronary Protection in the Women's Health Initiative Hormone Trials
Hsia et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:1666-1671.
ABSTRACT
| FULL TEXT
Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.
deGoma et al.
J Am Coll Cardiol 2008;51:2199-2211.
ABSTRACT
| FULL TEXT
Cardiovascular Events With Increased Lipoprotein-Associated Phospholipase A2 and Low High-Density Lipoprotein-Cholesterol: The Veterans Affairs HDL Intervention Trial
Robins et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:1172-1178.
ABSTRACT
| FULL TEXT
Laboratory Assessment of HDL Heterogeneity and Function
Movva and Rader
Clin. Chem. 2008;54:788-800.
ABSTRACT
| FULL TEXT
Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus
Davidson et al.
Circulation 2008;117:2123-2130.
ABSTRACT
| FULL TEXT
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation
Brunzell et al.
J Am Coll Cardiol 2008;51:1512-1524.
FULL TEXT
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
Brunzell et al.
Diabetes Care 2008;31:811-822.
FULL TEXT
HDL-cholesterol modulation and its impact on the management of cardiovascular risk
Ferns and Keti
Ann Clin Biochem 2008;45:122-128.
ABSTRACT
| FULL TEXT
Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol.
deGoma et al.
J Am Coll Cardiol 2008;51:49-55.
ABSTRACT
| FULL TEXT
Review: The role of fenofibrate in reducing cardiovascular risk in type 2 diabetes
Pedro-Botet
British Journal of Diabetes & Vascular Disease 2008;8:22-27.
ABSTRACT
Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?
Barter and Rye
Arterioscler. Thromb. Vasc. Bio. 2008;28:39-46.
ABSTRACT
| FULL TEXT
Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease
Mudd et al.
J Am Coll Cardiol 2007;50:1735-1741.
ABSTRACT
| FULL TEXT
Gemfibrozil Ameliorates Relapsing-Remitting Experimental Autoimmune Encephalomyelitis Independent of Peroxisome Proliferator-Activated Receptor-{alpha}
Dasgupta et al.
Mol. Pharmacol. 2007;72:934-946.
ABSTRACT
| FULL TEXT
Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women
Nordestgaard et al.
JAMA 2007;298:299-308.
ABSTRACT
| FULL TEXT
Triglycerides and Risk for Coronary Heart Disease
McBride
JAMA 2007;298:336-338.
FULL TEXT
The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease
Windler et al.
Diabetes and Vascular Disease Research 2007;4:136-142.
ABSTRACT
Reconstituted High-Density Lipoprotein Stimulates Differentiation of Endothelial Progenitor Cells and Enhances Ischemia-Induced Angiogenesis
Sumi et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:813-818.
ABSTRACT
| FULL TEXT
Prevalence and Treatment of Low HDL Cholesterol Among Primary Care Patients With Type 2 Diabetes: An unmet challenge for cardiovascular risk reduction
Grant and Meigs
Diabetes Care 2007;30:479-484.
ABSTRACT
| FULL TEXT
Rational therapy of mixed dyslipidaemia in a patient with diabetes
Reasner
British Journal of Diabetes & Vascular Disease 2007;7:25-30.
ABSTRACT
Diabetic dyslipidaemia: the triad
Wierzbicki
Eur Heart J Suppl 2006;8:F30-F33.
ABSTRACT
| FULL TEXT
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
Kontush and Chapman
Pharmacol. Rev. 2006;58:342-374.
ABSTRACT
| FULL TEXT
An Increased Coronary Risk Is Paradoxically Associated with Common Cholesteryl Ester Transfer Protein Gene Variations That Relate to Higher High-Density Lipoprotein Cholesterol: A Population-Based Study
Borggreve et al.
J. Clin. Endocrinol. Metab. 2006;91:3382-3388.
ABSTRACT
| FULL TEXT
Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment
Pedersen et al.
Diabetes and Vascular Disease Research 2006;3:S1-S12.
ABSTRACT
Hypertriglyceridemia.
Pejic and Lee
J Am Board Fam Med 2006;19:310-316.
ABSTRACT
| FULL TEXT
Cardioprotective Properties of Fibrates: Which Fibrate, Which Patients, What Mechanism?
Barter and Rye
Circulation 2006;113:1553-1555.
FULL TEXT
Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial
Otvos et al.
Circulation 2006;113:1556-1563.
ABSTRACT
| FULL TEXT
Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action
Clark et al.
J. Lipid Res. 2006;47:537-552.
ABSTRACT
| FULL TEXT
Peroxisome Proliferator-Activated Receptors and Liver X Receptors in Atherosclerosis and Immunity
Barish
J. Nutr. 2006;136:690-694.
ABSTRACT
| FULL TEXT
Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease
Barter and Kastelein
J Am Coll Cardiol 2006;47:492-499.
ABSTRACT
| FULL TEXT
Role of the Estrogen and Progestin in Hormonal Replacement Therapy on Apolipoprotein A-I Kinetics in Postmenopausal Women
Lamon-Fava et al.
Arterioscler. Thromb. Vasc. Bio. 2006;26:385-391.
ABSTRACT
| FULL TEXT
Muraglitazar, a Novel Dual ({alpha}/{gamma}) Peroxisome Proliferator-Activated Receptor Activator, Improves Diabetes and Other Metabolic Abnormalities and Preserves {beta}-Cell Function in db/db Mice
Harrity et al.
Diabetes 2006;55:240-248.
ABSTRACT
| FULL TEXT
Reverse cholesterol transport and cholesterol efflux in atherosclerosis
Ohashi et al.
QJM 2005;98:845-856.
ABSTRACT
| FULL TEXT
Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B in the Prediction of Coronary Heart Disease in Men
Pischon et al.
Circulation 2005;112:3375-3383.
ABSTRACT
| FULL TEXT
Lipids for Psychiatrists - an overview
Young
J Psychopharmacol 2005;19:66-75.
ABSTRACT
Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux
Asztalos et al.
J. Lipid Res. 2005;46:2246-2253.
ABSTRACT
| FULL TEXT
Fat, Fit, and Leading the Charge: The Evolution of Measuring High-Density Lipoprotein Subpopulations
Nambi and Ballantyne
Arterioscler. Thromb. Vasc. Bio. 2005;25:2013-2015.
FULL TEXT
2nd International Symposium on Triglycerides and HDL: Metabolic syndrome
Bloomgarden
Diabetes Care 2005;28:2577-2584.
FULL TEXT
Low HDL Cholesterol Levels
Ashen and Blumenthal
NEJM 2005;353:1252-1260.
FULL TEXT
PPAR{alpha}, but not PPAR{gamma}, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia
Hennuyer et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:1897-1902.
ABSTRACT
| FULL TEXT
Hyperglycemia, Lipoprotein Glycation, and Vascular Disease
Veiraiah
ANGIOLOGY 2005;56:431-438.
ABSTRACT
The Effect of Cholesteryl Ester Transfer Protein -629C->A Promoter Polymorphism on High-Density Lipoprotein Cholesterol Is Dependent on Serum Triglycerides
Borggreve et al.
J. Clin. Endocrinol. Metab. 2005;90:4198-4204.
ABSTRACT
| FULL TEXT
Raising HDL-cholesterol and lowering CHD risk: does intervention work?
Shepherd
Eur Heart J Suppl 2005;7:F15-F22.
ABSTRACT
| FULL TEXT
Antiatherogenic Properties of Fibrates
Barter
Arterioscler. Thromb. Vasc. Bio. 2005;25:1095-1096.
FULL TEXT
Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion
Brousseau et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:1057-1064.
ABSTRACT
| FULL TEXT
Review: Defining the role of statins in diabetes
Tuomilehto and Leiter
British Journal of Diabetes & Vascular Disease 2005;5:55-62.
ABSTRACT
Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator-Activated Receptor {alpha} Modulation
Duez et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:585-591.
ABSTRACT
| FULL TEXT
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials
Birjmohun et al.
J Am Coll Cardiol 2005;45:185-197.
ABSTRACT
| FULL TEXT
Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care
Feig et al.
CMAJ 2005;172:177-180.
FULL TEXT
Predictors of Health Care Costs in Adults With Diabetes
Gilmer et al.
Diabetes Care 2005;28:59-64.
ABSTRACT
| FULL TEXT
The role of dyslipidaemia in coronary heart disease
Wierzbicki
British Journal of Diabetes & Vascular Disease 2005;5:S2-S6.
ABSTRACT
Raising HDL-C and lowering triglycerides: benefits beyond LDL-C modification
Shepherd
British Journal of Diabetes & Vascular Disease 2005;5:S12-S16.
ABSTRACT
PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis
Li and Glass
J. Lipid Res. 2004;45:2161-2173.
ABSTRACT
| FULL TEXT
Dyslipidemia and the Metabolic Syndrome
Bloomgarden
Diabetes Care 2004;27:3009-3016.
FULL TEXT
Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia
Meagher
J Am Board Fam Med 2004;17:424-437.
ABSTRACT
| FULL TEXT
Prevention and Treatment of the Metabolic Syndrome
Daskalopoulou et al.
ANGIOLOGY 2004;55:589-612.
ABSTRACT
Prevention and Treatment of the Metabolic Syndrome
Daskalopoulou et al.
ANGIOLOGY 2004;55:589-612.
ABSTRACT
HDL Cholesterol and Protective Factors in Atherosclerosis
Assmann and Gotto
Circulation 2004;109:III-8-III-14.
ABSTRACT
| FULL TEXT
Beyond the Laboratory: Clinical Implications for Statin Pleiotropy
Halcox and Deanfield
Circulation 2004;109:II-42-II-48.
ABSTRACT
| FULL TEXT
Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study
Colquhoun et al.
Eur Heart J 2004;25:771-777.
ABSTRACT
| FULL TEXT
New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
McKenney
Arch Intern Med 2004;164:697-705.
ABSTRACT
| FULL TEXT
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau et al.
NEJM 2004;350:1505-1515.
ABSTRACT
| FULL TEXT
Clinical Trials and Lipid Guidelines for Type II Diabetes
Prisant
J Clin Pharmacol 2004;44:423-430.
ABSTRACT
| FULL TEXT
Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report and update
Gotto and Brinton
J Am Coll Cardiol 2004;43:717-724.
ABSTRACT
| FULL TEXT
Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values
Tsimihodimos et al.
J CARDIOVASC PHARMACOL THER 2004;9:27-33.
ABSTRACT
Antioxidative Activity of HDL Particle Subspecies Is Impaired in Hyperalphalipoproteinemia: Relevance of Enzymatic and Physicochemical Properties
Kontush et al.
Arterioscler. Thromb. Vasc. Bio. 2004;24:526-533.
ABSTRACT
| FULL TEXT
Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib
Clark et al.
Arterioscler. Thromb. Vasc. Bio. 2004;24:490-497.
ABSTRACT
| FULL TEXT
Is high-density lipoprotein the protector of the cardiovascular system?
Barter
Eur Heart J Suppl 2004;6:A19-A22.
ABSTRACT
| FULL TEXT
Decoding Transcriptional Programs Regulated by PPARs and LXRs in the Macrophage: Effects on Lipid Homeostasis, Inflammation, and Atherosclerosis
Ricote et al.
Arterioscler. Thromb. Vasc. Bio. 2004;24:230-239.
ABSTRACT
| FULL TEXT
The Metabolic Syndrome: Pathophysiology, Clinical Relevance, and Use of Niacin
Ito
The Annals of Pharmacotherapy 2004;38:277-285.
ABSTRACT
| FULL TEXT
Aspects of Blood Pressure, Lipid, and Glycemic Treatment
Bloomgarden
Diabetes Care 2004;27:264-269.
FULL TEXT
Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPAR{alpha} and {gamma} Agonist in Healthy Subjects and Patients with Type 2 Diabetes
Skrumsager et al.
J Clin Pharmacol 2003;43:1244-1256.
ABSTRACT
| FULL TEXT
Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress
Kontush et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:1881-1888.
ABSTRACT
| FULL TEXT
Assessing the Validity of Published Randomized Controlled Trials in Podiatric Medical Journals
Turlik et al.
J. Am. Podiatr. Med. Assoc. 2003;93:392-398.
ABSTRACT
| FULL TEXT
Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension: A double-blind, placebo-controlled study
Winkler et al.
Diabetes Care 2003;26:2588-2594.
ABSTRACT
| FULL TEXT
Medical Management of Hyperlipidemia/Dyslipidemia
Kreisberg and Oberman
J. Clin. Endocrinol. Metab. 2003;88:2445-2461.
FULL TEXT
Raising high-density lipoprotein cholesterol: where are we now?
Ballantyne
Eur Heart J Suppl 2003;5:D17-D25.
ABSTRACT
Review: Reconsidering the value of fibrates: lessons from the trials
Barter
British Journal of Diabetes & Vascular Disease 2003;3:162-167.
ABSTRACT
Pharmacological management of hyperlipidaemia
Evans et al.
British Journal of Diabetes & Vascular Disease 2003;3:204-210.
ABSTRACT
Insulin Resistance and Cardiovascular Events With Low HDL Cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT)
Robins et al.
Diabetes Care 2003;26:1513-1517.
ABSTRACT
| FULL TEXT
Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease: The Diabetes Atherosclerosis Intervention Study (DAIS)
Vakkilainen et al.
Circulation 2003;107:1733-1737.
ABSTRACT
| FULL TEXT
Gemfibrozil Reduces Plasma C-Reactive Protein Levels in Abdominally Obese Men With the Atherogenic Dyslipidemia of the Metabolic Syndrome
Despres et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:702-703.
FULL TEXT
Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism
Ma et al.
Proc. Natl. Acad. Sci. USA 2003;100:2748-2753.
ABSTRACT
| FULL TEXT
Targeted Replacement of Mouse Apolipoprotein A-I with Human ApoA-I or the Mutant ApoA-IMilano. EVIDENCE OF APOA-IM IMPAIRED HEPATIC SECRETION
Parolini et al.
J. Biol. Chem. 2003;278:4740-4746.
ABSTRACT
| FULL TEXT
Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force
Harris et al.
ANN INTERN MED 2003;138:215-229.
ABSTRACT
| FULL TEXT
Triglyceride-Rich Lipoproteins and Vascular Function
Haynes
Arterioscler. Thromb. Vasc. Bio. 2003;23:153-155.
FULL TEXT
Diabetes, Plasma Insulin, and Cardiovascular Disease: Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)
Rubins et al.
Arch Intern Med 2002;162:2597-2604.
ABSTRACT
| FULL TEXT
|
